Navigator Medicines focuses on developing biologics to modulate and restore immune function for complex, heterogeneous autoimmune diseases. The company in‑licensed NAV-240, a clinical‑stage bispecific antibody targeting OX40L and TNFα, and an OX40L‑targeted portfolio from IMBiologics. NAV-240’s dual targeting of OX40L and TNFα is intended to improve on monotherapy efficacy for inflammatory diseases. Navigator plans to initiate additional clinical studies with NAV-240 in the coming months and advance other programs in its pipeline. The company was founded in 2024 as a subsidiary of Sera Medicines and is based in Scotch Plains, N.J. Its recent financing will be used to accelerate clinical development and broader pipeline advancement.

Total raised

$100M

Funding rounds

1

Latest round

Series A

Latest activity

Aug 2024